RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
Market Cap
$107.86M
MomentumView details →
1D Return
+0.84%
YTD Return
+177.94%
RSI (14)
77.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
Market Cap
$107.86M
RSI (14)
77.5
MomentumView details →
1D Return
+0.84%
YTD Return
+177.94%
SummaryUpdated Jun 1, 2026
RenovoRx, Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Los Altos, California. The company went public in August 2021 and focuses on developing innovative therapies for treating solid tumors, particularly pancreatic cancer. RenovoRx has developed a unique approach combining drug delivery devices with chemotherapy medications to improve treatment outcomes while reducing side effects for cancer patients.
Similar companies
Latest newsMore news →
RenovoRx received written notification from Nasdaq confirming it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.14d agoRenovoRx announced that its RenovoCath delivery device has expanded to 21 centers, indicating commercialization progress.19d agoRenovoRx delivered the first treatment with RenovoCath in a patient with sarcoma in a clinical setting, marking expansion of the device to other solid tumors.23d ago